🇺🇸 LNTH — Lantheus Holdings, Inc.

Salud Mantener
← Volver

Precio actual

100,80 USD

Máx. histórico

123,62

845 días

Caída desde máximo

-18,46%

Rango 52 semanas

50,16 – 111,86

Variación hoy

+0,49%

Cierre anterior

100,31

Rango de hoy

100,26 – 100,83

Volumen hoy

748.573

Peor caída histórica

-78,62%

17/08/2015 → 08/02/2016

Recuperado en 202 días

Volatilidad anualizada ⓘ

63,44%

Información
Nombre completo
Lantheus Holdings, Inc.
Divisa
USD
Mercado
NasdaqGM
Sector
Salud
Industria
Drug Manufacturers - Specialty & Generic
Empleados
1.193
PER ⓘ
24,41 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
106,99 USD (puede no estar actualizado)
Primera cotización
25/06/2015
Precio actualizado
hace 8 horas
Sobre la empresa

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
25/08/2025 58,00 58,66 55,86 56,16 -3,52% 4,82% 1.073.800
22/08/2025 59,03 60,14 58,07 58,21 -1,61% 3,51% 2.307.700
21/08/2025 55,96 59,22 55,56 59,16 +5,38% 6,54% 3.652.500
20/08/2025 55,00 57,06 55,00 56,14 +1,80% 3,75% 5.393.900
19/08/2025 55,91 56,00 55,09 55,15 -1,47% 1,64% 1.064.400
18/08/2025 54,59 56,16 54,21 55,97 +3,30% 3,57% 2.036.200
15/08/2025 54,52 54,85 53,39 54,18 -0,53% 2,68% 1.221.700
14/08/2025 53,26 54,49 52,87 54,47 +1,26% 3,04% 1.527.100
13/08/2025 53,57 53,89 51,40 53,79 -0,20% 4,64% 2.327.100
12/08/2025 55,02 55,65 52,75 53,90 -3,87% 5,27% 2.950.700
11/08/2025 56,85 57,12 54,79 56,07 -1,98% 4,10% 2.146.800
08/08/2025 54,90 57,21 53,69 57,20 +4,27% 6,41% 2.503.500
07/08/2025 53,65 55,74 52,93 54,86 +5,76% 5,23% 3.900.800
06/08/2025 51,58 52,33 47,25 51,87 -28,58% 9,85% 13.957.500
05/08/2025 71,73 73,72 71,23 72,63 +1,64% 3,48% 1.576.200
04/08/2025 70,81 71,58 70,05 71,46 +1,26% 2,16% 1.058.200
01/08/2025 70,77 71,17 69,45 70,57 -0,87% 2,42% 943.100
31/07/2025 71,05 72,00 70,77 71,19 -0,90% 1,74% 696.900
30/07/2025 71,93 72,80 71,68 71,84 -0,50% 1,56% 783.000
29/07/2025 73,04 73,18 71,88 72,20 -0,29% 1,79% 539.300
28/07/2025 73,05 73,52 72,15 72,41 -0,71% 1,88% 581.000
25/07/2025 71,42 73,06 70,83 72,93 +2,82% 3,12% 615.500
24/07/2025 72,69 73,00 70,40 70,93 -3,25% 3,58% 814.800
23/07/2025 72,76 73,58 72,23 73,31 +1,34% 1,85% 600.800
22/07/2025 71,52 72,58 70,73 72,34 +1,09% 2,59% 815.600
21/07/2025 70,20 71,80 69,93 71,56 +1,97% 2,66% 1.400.700
18/07/2025 74,47 74,47 69,88 70,18 -4,65% 6,16% 1.351.700
17/07/2025 74,41 74,98 72,91 73,60 -1,09% 2,78% 1.755.200
16/07/2025 78,15 78,15 69,12 74,41 -8,43% 11,55% 4.162.500
15/07/2025 83,20 83,32 80,88 81,26 -2,17% 2,93% 794.200